ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Hackensack, New Jersey 07601-2191, United States
Santiago Region Metropolitana, Santiago Metropolitan 8330034, Chile
La Tronche, Auvergne-Rhône-Alpes 38700, France
Saint Priest En Jarez, Pays de la Loire Region 42270, France
Meldola, Emilia-Romagna 47014, Italy
Osakasayama-shi, Osaka 5898511, Japan
Glasgow, South Western Scotland G611BD, United Kingdom
551-996-5863
503-215-3878
503-215-3878
615-986-0857
615-875-6814
61295150056
+617520203155
+56998744662
+33556795679
+33476767575
+4945150044101
49(0)69 6301 7860
390543739100
39050993251
6564368197
82317803928
+34915868308
88662353535x5389
8862231234567251
+886938590872
442033131000
441413017073